August 2012
-
In early April, up to 20 scientists and technicians from around the world will gather in a laboratory at the Firestone Institute for Respiratory Health for an intensive course known as “Aerosol School.” Over a… Read more . . .
-
According to Alexza Pharmaceuticals, the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for the Adasuve Staccato loxapine NDA from February 4, 2012 to May 4, 2012. On January 10, 2012, Alexza… Read more . . .
-
According to Insmed, the US FDA has lifted the clinical hold on Arikace liposomal amikacin for inhalation for the treatment of patients with non-tuberculous mycobacteria (NTM) lung disease. In October 2011, the FDA had asked… Read more . . .
-
As UK-based Prosonix transitions from a particle engineering specialist into a pharmaceutical company with three inhaled respiratory drugs in its pipeline, it has announced the appointment of Rob Crocker as its first Head of Regulatory… Read more . . .
-
Takeda Pharmaceutical has announced that it will lay off approximately 2,800 employees — 2,100 in Europe and 700 in the US — as it realigns to accommodate its 2011 acquisition of Nycomed. Nycomed’s products include… Read more . . .
-
Manufacturer Church & Dwight UK has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of possible bacterial contamination of its Sterimar Isotonic 100ml saline nasal spray, which is available over the counter in the… Read more . . .
-
After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the… Read more . . .
-
MAP Pharmaceuticals has appointed W. James O’Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O’Shea held a number of positions in operations and commercialization and… Read more . . .
-
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .
-
Applications due by January 31, 2012. Details of the award and submission information are avaiable on this document. The application form is available here. Applicants must work in academia or small and medium enterprises (SMEs)… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland